AbCellera Biologics Inc.
11.82USD
+0.4500 (+3.96%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ABCL.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 485.4M | 38.0M | 28.8M | 75.1M | 26.4M | 28.2M |
| Q1 | 316.6M | 12.2M | 10.0M | 4.2M | 8.3M | — |
| Q2 | 45.9M | 10.1M | 7.3M | 17.1M | 4.1M | — |
| Q3 | 101.4M | 6.6M | 6.5M | 9.0M | 6.2M | — |
| Q4 | 21.5M* | 9.2M* | 5.1M* | 44.9M* | 7.0M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | .500 | -.510 | -.550 | -.490 | -.674 | -.763 |
| Q1 | .540 | -.140 | -.140 | -.150 | -.140 | — |
| Q2 | -.020 | -.110 | -.130 | -.120 | -.180 | — |
| Q3 | .080 | -.100 | -.170 | -.190 | -.178 | — |
| Q4 | -.095* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.163* |
| -.116* |
| -.030* |
| -.172 |
| — |
Debt level and coverage